Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086522 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Qualigen Theraputics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 4
- Study locations
NCT06086522: Recruiting Phase 1 study of Solid Tumor, sponsored by Qualigen Theraputics.
NCT06086522 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Qualigen Theraputics. The registered enrollment target is 54 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06086522, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Qualigen Theraputics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 4
- Study locations
Study Summary
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.
Primary Outcome
maximum tolerated dose identified from dose escalation cohorts
Conditions Studied
Interventions
- DRUG QN-302
Study Locations (4)
Arizona
- HonorHealth - Scottsdale
Connecticut
- Yale - New Haven
Michigan
- START Midwest - Grand Rapids
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06086522 shows while recruiting
NCT06086522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which QN-302 is the first listed.
NCT06086522 reports a single indexed study location in Arizona, Connecticut, Michigan.
Frequently Asked Questions
What is clinical trial NCT06086522 about?
NCT06086522 is a clinical study titled "Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors". Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intrav...
What is the current status of trial NCT06086522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-11-01. Estimated completion is 2026-12.
What conditions does trial NCT06086522 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06086522?
The interventions under investigation include: QN-302 (DRUG).
Who is sponsoring clinical trial NCT06086522?
This trial is sponsored by Qualigen Theraputics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06086522 being conducted?
This trial has 4 study locations across Arizona, Connecticut, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06086522's enrollment target sits among peer trials
54 117th of 196 higher than 78 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI